This HTML5 document contains 88 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00780/identifier/pharmgkb/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00780/identifier/kegg-compound/
n10http://linked.opendata.cz/resource/AHFS/
n24http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00780/identifier/bindingdb/
n20http://linked.opendata.cz/resource/drugbank/dosage/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00780/identifier/pubchem-compound/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00780/identifier/pubchem-substance/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00780/identifier/drugbank/
n11http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n15http://linked.opendata.cz/resource/drugbank/drug/DB00780/identifier/national-drug-code-directory/
n5http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n22http://linked.opendata.cz/resource/drugbank/drug/DB00780/identifier/chemspider/
n3http://linked.opendata.cz/ontology/drugbank/
n27http://www.drugs.com/cdi/
n18http://www.rxlist.com/cgi/generic2/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n9http://linked.opendata.cz/resource/atc/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00780/identifier/wikipedia/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00780
rdf:type
n3:Drug
n3:description
An irreversible non-selective inhibitor of monoamine oxidase. May be used to treat major depressive disorder.
n3:dosage
n20:271B5F2F-363D-11E5-9242-09173F13E4C5 n20:271B5F30-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Nolen WA: [Classical monoamine oxidase inhibitor: not registered for, but still a place in the treatment of depression] Ned Tijdschr Geneeskd. 2003 Oct 4;147(40):1940-3. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14574774 # Sowa BN, Holt A, Todd KG, Baker GB: Monoamine oxidase inhibitors, their structural analogues, and neuroprotection. Indian J Exp Biol. 2004 Sep;42(9):851-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15462176
n3:group
approved
n3:halfLife
1.2-11.6 hours following single dose administration. Multiple-dose pharmacokinetics have not been studied.
n3:indication
For the treatment of major depressive disorder. Has also been used with some success in the management of bulimia nervosa.
n3:manufacturer
n24:271B5F2B-363D-11E5-9242-09173F13E4C5
owl:sameAs
n5:DB00780 n11:DB00780
dcterms:title
Phenelzine
adms:identifier
n13:3675 n14:46507348 n15:0071-0350-60 n16:PA450903 n19:50105417 n21:C07430 n22:3547 n23:DB00780 n25:Phenelzine
n3:mechanismOfAction
Although the exact mechanism of action has not been determined, it appears that the irreversible, nonselective inhibition of MAO by phenelzine relieves depressive symptoms by causing an increase in the levels of serotonin, norepinephrine, and dopamine in the neuron.
n3:packager
n24:271B5F29-363D-11E5-9242-09173F13E4C5 n24:271B5F2A-363D-11E5-9242-09173F13E4C5 n24:271B5F27-363D-11E5-9242-09173F13E4C5 n24:271B5F28-363D-11E5-9242-09173F13E4C5 n24:271B5F25-363D-11E5-9242-09173F13E4C5 n24:271B5F26-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
NARDIL ® is extensively metabolized, primarily by oxidation via monoamine oxidase.
n3:synonym
SID11111654 SID11111653 Nardil Phenelzin Phénelzine β-Phenylethylhydrazine SID90341694 Fenelzina Phenelzinum SID50111200 Monofen Alazine
n3:toxicity
Symptoms of overdose include drowsiness, dizziness, faintness, irritability, hyperactivity, agitation, severe headache, hallucinations, trismus, opisthotonos, convulsions and coma, rapid and irregular pulse, hypertension, hypotension and vascular collapse, precordial pain, respiratory depression and failure, hyperpyrexia, diaphoresis, and cool, clammy skin. Hypertensive crisis may occur with the ingestion of tyramine-rich foods such as cured meats, poultry or fish, aged cheeses, concentrated soy products, tap beer and wine, yeast extracts, broad bean pods and fava beans and sauerkraut.
n8:hasAHFSCode
n10:28-16-04-12
n3:foodInteraction
Avoid aged foods (cheese, red wine), pickled foods, cured foods (bacon/ham), chocolate, fava beans, beer, unless approved by your physician. Avoid alcohol. Avoid St.John's Wort. Avoid excessive quantities of coffee or tea (Caffeine). Take without regard to meals.
n3:salt
foaf:page
n18:phenelzine.htm n27:phenelzine.html
n3:IUPAC-Name
n6:271B5F35-363D-11E5-9242-09173F13E4C5
n3:InChI
n6:271B5F3B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n6:271B5F3A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n6:271B5F37-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n6:271B5F38-363D-11E5-9242-09173F13E4C5
n3:SMILES
n6:271B5F39-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n6:271B5F33-363D-11E5-9242-09173F13E4C5 n6:271B5F4A-363D-11E5-9242-09173F13E4C5
n3:logP
n6:271B5F34-363D-11E5-9242-09173F13E4C5 n6:271B5F31-363D-11E5-9242-09173F13E4C5 n6:271B5F4D-363D-11E5-9242-09173F13E4C5
n3:logS
n6:271B5F32-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n9:N06AF03
n3:H-Bond-Acceptor-Count
n6:271B5F41-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n6:271B5F42-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n6:271B5F3C-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n6:271B5F3D-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n6:271B5F3F-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n6:271B5F3E-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n6:271B5F40-363D-11E5-9242-09173F13E4C5
n3:absorption
Readily absorbed after oral administration.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
51-71-8
n3:category
n3:containedIn
n7:271B5F2D-363D-11E5-9242-09173F13E4C5 n7:271B5F2E-363D-11E5-9242-09173F13E4C5 n7:271B5F2C-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n6:271B5F46-363D-11E5-9242-09173F13E4C5
n3:Boiling-Point
n6:271B5F4C-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n6:271B5F48-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n6:271B5F49-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n6:271B5F4B-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n6:271B5F45-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n6:271B5F44-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n6:271B5F47-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n6:271B5F36-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n6:271B5F43-363D-11E5-9242-09173F13E4C5